Emergings In Brief, May 2015
This article was originally published in Start Up
Brief profiles of these recently formed companies: Admera Health, Denali Therapeutics, Esperas Pharma, and OccuRx.
You may also be interested in...
Many Aurora kinase inhibitors have entered development, but while none have had a successful end, Lilly believes the specificity of AurKa's AK-01 will make it a safer drug. The asset fits well into Lilly's oncology strategy, which includes both targeted therapies and immuno-oncology drugs.
In Vivo's editors pick January's most significant deals, including an alliance of players new to health care and Celgene's big buys. (Free article.)